Cargando…
Immunotherapy: TREATMENT WITH ALLOCETRA-OTS APOPTOTIC CELLS IN 21 SEVERELY/CRITICALLY ILL PATIENTS WITH COVID-19
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
International Society for Cell & Gene Therapy. Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035734/ http://dx.doi.org/10.1016/S1465-3249(22)00328-0 |
| _version_ | 1784693362323881984 |
|---|---|
| author | Mevorach, D. |
| author_facet | Mevorach, D. |
| author_sort | Mevorach, D. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9035734 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | International Society for Cell & Gene Therapy. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90357342022-04-25 Immunotherapy: TREATMENT WITH ALLOCETRA-OTS APOPTOTIC CELLS IN 21 SEVERELY/CRITICALLY ILL PATIENTS WITH COVID-19 Mevorach, D. Cytotherapy POSTER ABSTRACTS: Immunotherapy International Society for Cell & Gene Therapy. Published by Elsevier Inc. 2022-05 2022-04-25 /pmc/articles/PMC9035734/ http://dx.doi.org/10.1016/S1465-3249(22)00328-0 Text en Copyright © 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | POSTER ABSTRACTS: Immunotherapy Mevorach, D. Immunotherapy: TREATMENT WITH ALLOCETRA-OTS APOPTOTIC CELLS IN 21 SEVERELY/CRITICALLY ILL PATIENTS WITH COVID-19 |
| title | Immunotherapy: TREATMENT WITH ALLOCETRA-OTS APOPTOTIC CELLS IN 21 SEVERELY/CRITICALLY ILL PATIENTS WITH COVID-19 |
| title_full | Immunotherapy: TREATMENT WITH ALLOCETRA-OTS APOPTOTIC CELLS IN 21 SEVERELY/CRITICALLY ILL PATIENTS WITH COVID-19 |
| title_fullStr | Immunotherapy: TREATMENT WITH ALLOCETRA-OTS APOPTOTIC CELLS IN 21 SEVERELY/CRITICALLY ILL PATIENTS WITH COVID-19 |
| title_full_unstemmed | Immunotherapy: TREATMENT WITH ALLOCETRA-OTS APOPTOTIC CELLS IN 21 SEVERELY/CRITICALLY ILL PATIENTS WITH COVID-19 |
| title_short | Immunotherapy: TREATMENT WITH ALLOCETRA-OTS APOPTOTIC CELLS IN 21 SEVERELY/CRITICALLY ILL PATIENTS WITH COVID-19 |
| title_sort | immunotherapy: treatment with allocetra-ots apoptotic cells in 21 severely/critically ill patients with covid-19 |
| topic | POSTER ABSTRACTS: Immunotherapy |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035734/ http://dx.doi.org/10.1016/S1465-3249(22)00328-0 |
| work_keys_str_mv | AT mevorachd immunotherapytreatmentwithallocetraotsapoptoticcellsin21severelycriticallyillpatientswithcovid19 |